Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC).
Vokes, E Socinski, M Spigel, D Paz-Ares, L Kurek, R Nanda, S Grau, G Shahidi, J Thatcher, Nick Gandara, D
Vokes, E
Socinski, M
Spigel, D
Paz-Ares, L
Kurek, R
Nanda, S
Grau, G
Shahidi, J
Thatcher, Nick
Gandara, D
Citations
Altmetric:
Abstract
Description
Date
2016-10-01
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC). 2016, 27(suppl_6):1256P Annals of Oncology